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ABSTRACT

Historically, women as subjects have been underrepresented in clinical research.
Due to this problem, legislation was enacted by Congress in 1993 to require inclusion of
women in NIH funded clinical trials. Female animals are also underrepresented in
preclinical research and need to be included to ensure safe and effective drugs. Studies
exclude female mammals under the assumption that the estrus cycle contributes to
variability (Beery, 2011). This notion has been contradicted by several studies
(Prendergast, 2014; Becker, 2016). New requirements of NIH funded researchers to
consider sex as a basic biological variable were announced in 2014 (Clayton, 2014). As
of June 5. 2016, all NIH grant applications must include plans to use equal numbers of
both sexes and to perform statistical analysis for possible sex differences (NIH, 2016).
This study examined the impact that these requirements have had on the inclusion
of both sexes and the analysis of sex differences in preclinical research. The fields of
neuroscience, pharmacology, and immunology were chosen for analysis based on
research indicating that they had the lowest rates of analyzing sex differences prior to the
mandate (Beery, 2011). A significant increase in the inclusion of both sexes was found in
all fields (p<0.001), along with a 3.58 fold increase in the proportion of articles that
analyzed sex differences. NIH funded pharmacology research was more likely to include
both sexes and report sex difference analyses post-mandate. However, articles still must
analyze sex differences and include both sexes at a much higher rate than the current
2018 statistics calculated in this analysis (16.4% and 36.4%).Due to the recentness of the
mandate, it is recommended that a follow-up study be conducted. The increases in female
inclusion and sex differences analysis are promising signs of future improvement.
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INTRODUCTION

Historically, female mammals are excluded from preclinical research due to the
assumption that results from males apply to females, and concerns that hormonal cycles
increase variability in samples and confound experimental manipulations (Beery, 2011).
It is not only female animals that have been historically excluded from research. In 1977,
the FDA advised the exclusion of women of child bearing age from drug trials due to
possible effects of experimental medications on fertility and pregnancy (US Food and
Drug Administration). These recommendations led to underrepresentation of women in
clinical research for decades (Beery, 2011). Of drugs withdrawn from the US market
from 1997–2000, the US Government Accountability Office reported that 8 out of 10
drugs taken off the market had greater adverse effects in women (Simon, 2005). Without
proper representation of women and female animals in research, the general public is put
at risk.
The notion of the 78 kg white man as the norm for research is harmful to women
and minorities. For example, crash test dummies have been based off the biometrics to
the average male for the past thirty years (Bose, 2011). As a result, seat-belted women are
47 percent more likely to have serious injuries in accidents (Bose, 2011). Basing research
off of just men has also led to bias in the way that female patients are diagnosed in
diseases like coronary heart disease (CHD) and Attention-Deficit/Hyperactivity Disorder
(ADHD) (Mikhail, 2005;Walters, 2018). In women, coronary heart disease presents
differently than the clinical symptoms that have been classified in men (Mikhail, 2005).
CHD kills an equal or higher percentage of women compared to men, yet the general
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public still refers to heart health as a predominantly male disease (Mikhail, 2005).
Sources also indicate that up to three quarters of women and girls with ADHD go
undiagnosed due to symptoms mischaracterized as laziness or introversion (Walters,
2018).
The bias of using men as a model for human disease has also affected the dosage
of certain drugs and vaccines (Klein, 2016). Legislation has been in place to increase
diversity in US clinical trials since the 1993 NIH Revitalization Act passed by Congress.
This legislation has caused the proportion of women in clinical trials to increase to 50%
(Beery, 2011). Likewise, as new rules such as the NIH mandate are instituted the hope is
that female animal representation in preclinical research will reach 50 percent. The plan
to enforce these rules revolves around data mining techniques by the NIH. The NIH aims
to keep researchers accountable by monitoring when studies do not include both sexes or
analyze sex differences; however, no repercussions for this have been indicated (Clayton,
2014). If the mandate is not enough to increase female inclusion, it may be recommended
that legislation be enacted.
In May 2014, the National Institutes of Health announced that the agency planned
to ensure that investigators account for sex as a basic biological variable (SABV) in NIHfunded preclinical research (Clayton, 2014). As of June 2016, all NIH grant applications
must include plans to use equal numbers of each sex and to perform statistical analysis
for possible sex differences (NIH, 2016). This mandate was influenced by a 2011 metaanalysis which revealed a male bias in 8 out of 10 biological disciplines (Beery, 2011).
To address the issue of underrepresentation of female animals and analyze the effects of
the NIH mandate, a meta-analysis of the most disparate biomedical fields was conducted.
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The fields of neuroscience, pharmacology, and immunology were chosen for analysis
based on research indicating that they had the lowest rates of analyzing sex differences
prior to the mandate (Beery, 2011). It was hypothesized that research funded by the NIH
would be more inclusive of sex and have a larger increase in the inclusion of females than
research with other sources of funding.
The plan to include sex as a basic biological variable (SABV) in all grant
applications was officially implemented for the fiscal year of 2017. The SABV policy
requires researchers to factor sex into the design, analysis, and reporting of vertebrate
animal and human studies (NIH, 2016). This meta-analysis aimed to assess the current
state of sex inclusion in biomedical research. Three of the previously most disparate
disciplines identified by Beery (2011) were analyzed: immunology, pharmacology, and
neuroscience. According to data from 2009, these three disciplines analyzed for sex
differences less than ten percent of the time, the least out of ten biomedical fields
analyzed (Beery, 2011). Furthermore, males were specified in 65 percent of
pharmacology articles while females were included in only 20 percent, with 15 percent of
articles not specifying sex (Beery, 2011). Less than 10 percent of articles in these fields
analyzed sex differences (Beery, 2011). Articles in immunology use only females more
often than only males. Over 60 percent of articles did not specify what sexes were used
(Beery, 2011). For neuroscience, 25 percent of articles did not specify sex and 55 percent
of articles used only males (Beery, 2011).
The consequence of using only one sex in preclinical research is that important
differences between male and female organisms are being neglected. Estrogen and
testosterone play important roles in both sexes’ bodies, however the levels and roles of
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these hormones are different between men and women. For example, in males
testosterone is first converted into estradiol by aromatase to masculinize the brain.
Estrogen affects a wide variety of processes including neuronal differentiation and innate
immunity. Due to the effects of estrogen, women have more reactive innate immune
systems than men, leading to more adverse reactions to vaccines (Klein, 2016).
The pressure on researchers to produce statistically significant results may have
an impact on how they approach the topic of choosing animals to include in their
analysis. Some have argued that using only male animals increases reproducibility due to
the estrus cycle of female mammals possibly adding variance in results. This notion has
been contradicted by four studies of mice and rats (Becker, 2016; Prendergast, 2014; Itoh,
2015; Meziane, 2007). A meta-analysis of neuroscience articles indicated that studies that
used both male and female rats, with no regard to estrus staging, were no more variable
than studies that used only males (Becker, 2016). P values ranged from 0.6 to 0.95 when
conducting a standard t-test on the trait variance of neurobehavioral measures in males
versus females (Becker, 2016).
A meta-analysis of whether monitoring the estrous cycle reduces variability of
results found that females at any point in estrus were no more variable than males. This
opposes the idea that if females are included in research, they need to be studied at the
four different phases of estrous (Prendergast, 2014). This study also found that group
housing increased trait variability by 37 percent. This is a much larger amount of
variability added to experimental designs than including both sexes. Furthermore, it
should be noted that individual differences create variability in experimental results.
Studying both sexes is just one way to increase the generalizability to a population. For
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example, when studying certain antidepressants in males, the results do not have any
predictive relevance to the clinical outcomes of females (Koren, 2014).
Lastly, a meta-analysis of microarray gene expression datasets (5 million probes),
found that in both mice and humans females were very slightly less variable than males
(Itoh, 2015). However, when looking a tissue specific microarrays, males were more
variable in spleen tissue and females were more variable in adrenal tissue. These findings
support the opinion that one sex is not more variable than the other. On the contrary, sex
differences are ubiquitous and need to be examined on a molecular, cellular and
organismal level.
Sex-based differences in disease are consequences of X chromosome inactivation,
differences in quantities of hormones, and differences in anatomy. Immunology may be
the field with the most pronounced sex differences out of the three. There are 60 known
genes carried on the X chromosome that are involved in immune regulation (Klein,
2016). X chromosome inactivation likely is the largest factor when it comes to sex
differences in immunity (Klein, 2016). Females have higher expression of genes on the
X-chromosome which include immune markers like FoxP3 and CD40L. Females produce
higher Th2 response and antibodies. This leads to better protection from infections but
their hyperimmune responses increase susceptibility to autoimmune diseases (Taneja,
2018).
Klinefelter’s syndrome, which occurs when males have an extra X chromosome,
leads to many immunological changes. This condition results in low testosterone,
increased gonadotrophins, and elevated estrogen concentrations (Ko’ar, 2000). Due to
these hormonal and cellular differences, men with Klinefelter’s syndrome respond with
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higher immunoglobulin concentrations, CD4+ T cell numbers, CD4/CD8 T cell ratios,
and B cell numbers than XY males (Ko’ar, 2000). Furthermore, the immunological
effects of Klinefelter’s syndrome are reversed by testosterone therapy. This illustrates the
important role of hormones in immunity. Moreover, women with Turner syndrome
(nondisjunction error resulting in X0 instead of XX) have lower IgG and IgM levels and
lower T cell and B cell levels compared to XX females (Klein, 2016). Interestingly, both
patients with Klinefelter’s syndrome and patients with Turner syndrome show increased
development of autoimmune disease. This illustrates the major role of the X chromosome
in susceptibility to autoimmune diseases (Klein, 2016). Estrogen also plays a major role
in autoimmune diseases such as Grave’s disease, systemic lupus erythematosus, and
multiple sclerosis (Klein, 2016).
In general, both the proportion of individuals infected and the severity of infection
are higher in males than females for viral, bacterial, fungal, and parasitic diseases (Klein,
2016). Pro-inflammatory cytokine responses, T cell proliferation, and antibody responses
are also greater in female mice than male mice (Klein, 2016). Furthermore, there are
variations in estrogen and progesterone levels during the different phases of the menstrual
cycle. These hormones influence t-helper 1, t-helper 2, and t- regulatory cell populations.
T-reg and TH2 cells are associated with peaks in estrogen while TH1 cell levels drop
during estrogen peaks (Klein, 2016). However, predictable hormonal changes do not
make females any more variable than males (Becker, 2016). The sex differences in
immunology are diverse and ubiquitous throughout the body. Research on both sexes is
imperative to fully understand these differences.
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Sex differences exist in every part of the brain, including the hippocampus,
amygdala, and neocortex (Andreano, 2009). Functional cerebral asymmetries are more
common in males than in females, meaning that functions such as speech or facial
recognition are lateralized to one side (Killgore, 2001). When men perceive happy faces
versus fearful faces, amygdala activation is lateralized to either side according to fMRI
data. However, when women see the same image there is no significant difference in the
areas of the amygdala activated (Killgore, 2001).
It is no secret that there are psychosocial, language, and memory differences
between men and women (Andreano, 2009). Although some of these differences can be
attributed to hormones, there are ubiquitous sex differences throughout the nervous
system, from the anatomical to subcellular level. The gonadal steroid estrogen has been
shown to affect neuronal growth, differentiation and survival at every point in
development (Abel, 2010). Research has also shown that estrogen protects cortical
neurons from glutamate toxicity (Singer, 1996).
The male brain is masculinized by testosterone being converted to estradiol and
then crossing the blood brain barrier. Mechanisms for sex differences in the brain have
been proposed for both hormonal and molecular factors. Sex differences have been found
at the transcriptional level in zebrafish brains (Lee, 2018). Brain aromatase, prostaglandin
3a synthase, and prostaglandin reductase 1 are among the genes with sexually dimorphic
expression patterns. Furthermore, seven mouse genes have been found to show
differential expression between the developing brains of male and female mice at stage
10.5 days post coitum (dpc), before any gonadal hormone influence (Dewing, 2003). It is
believed that those genes are integral in brain sexual differentiation as determined by
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chromosomal sex. While my meta- analysis focused on in-vivo sex differences, it is
important to remember that sex differences can be apparent in in-vitro tissues and cell
cultures as illustrated in the prior study.
The consequences of failing to include sex-based differences in study design and
analyses has effectively led to treatment regimens that are identical for both men and
women. As a result of this bias, differences in drug efficacy and adverse effects
reportedly led to the withdrawal of eight out of ten prescription drugs from the United
States market in 2005, specifically owing to health issues in women (Simon, 2005).
Critics of sex-specific analysis claim that conducting scientifically rigorous trials with
enough statistical power to detect sex differences is inefficient in terms of time as well as
cost. Nevertheless, when prescription drugs are withdrawn from the U.S. market because
they cause greater health risks for women than men, the cost of not doing such analyses
becomes a greater liability for drug companies.
Arrhythmias due to atypical antipsychotics were found to be much more common
in women (Aichhorn, 2007). According to the FDA’s good laboratory practices for
preclinical research, which provides the basis for toxicity and dosing, it is not required
that research be conducted on both sexes of animals to be brought to clinical trials. Only
guidance for the ‘Animal Rule’—which allows experimental drugs to surpass the clinical
trial process if it is unethical to test on humans—requires testing on both sexes. However,
in the normal industry standards, there is no requirement for this. Not testing both sexes
can lead to adverse outcomes in the understudied sex during and after the clinical trial
process.
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There are sex differences other than adverse effects caused by drugs. Differences
in drug metabolism and absorption rate of certain drugs have been found. This has been
hypothesized to be due to X chromosome inactivation of certain CYP genes, which play a
major role in drug metabolism. The absorption rate and extent of a drug are drug-specific
so it is difficult to pick out blanket mechanisms different in men and women. Examples
of drugs that illustrate sex differences in drug absorption include, rifampicin, and IM
cephradine (Soldin, 2009). Increased absorption of rifampicin is seen in women (Gorksi,
2009). Lower bioavailability and absorption of intramuscular cephadrine was observed in
women. Furthermore, it is postulated that women, due to possessing larger amounts of
subcutaneous lipid content, receive different doses of transdermally administered drugs.
Additionally, women have greater respiratory minute ventilation and lower tidal volume,
which may result in decreased ingestion of inhaled aerosol drugs (Soldin, 2009).
Female enterocytes express significantly different levels of CYP3A isoenzymes
than males, which contribute the metabolism of many orally administered drugs (Soldin,
2009). Drug rate of absorption is influenced by multiple factors, including gut transit
times, lipid solubility and molecular weight of the drug, along with pH and motility of the
gut. Gastric fluids are more acidic in males than females. Reduced pH results in
decreased absorption of weak acids and increased absorption of weak bases. Transit times
are significantly different in men and women. Mean transit times are shorter in men than
in women; 44 hours compared to 92 hours (Soldin, 2009). It has also been found that
studying the dosage of certain antidepressants in males is completely irrelevant to the
clinical outcomes in females (Koren, 2014). Studying sex differences in all
pharmacological studies could lead to better clinical outcomes for women.
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In summary, a meta-analysis of three disparate fields identified by Beery was
conducted. Neuroscience, immunology and pharmacology all have widespread sex
differences which are worth analyzing in papers that are relevant to both men and
women. It was hypothesized that the inclusion of both sexes and sex differences analysis
would increase after the enactment of the mandate in 2016. Furthermore, it was expected
that NIH funded research would include both sexes and analyze sex differences more
often than research with other sources of funding.
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METHODS

Published papers in nine peer reviewed journals were evaluated for several
variables (See Table 1). The fields neuroscience, pharmacology, and immunology were
chosen to be the targets of the research based on Beery and Zucker’s 2011 paper
illustrating that these three fields had the largest discrepancies in the use of female versus
male animals. Three major journals from each field were selected for review. Then the
choice was made to use solely mice papers because mice are the most common model
organism for studying human disease (Spencer, 2002). Only papers dated from 2009 to
2018 were used.
Table 1: Number of Articles per Field
Field
Neuroscience
Journals Neuron: 471

Pharmacology
Journal of Medicinal Chemistry:
229

Neuroscience: 357
Nature Neuroscience:
258

Immunology
PloS Pathogens: 324
Vaccine: 169

British Journal of
Pharmacology: 81

Nature Immunology:
275

Neuropsychopharmacology: 169
Total

1082

474

766

Mice were chosen to be the organism of interest for this study due to immunology
using primarily mice as subjects (Beery, 2011). Furthermore, the use of mice as a model
organism has drastically risen since 1990. The mouse has surpassed the rat as the most
popular animal model (Spencer, 2002). Because in this meta-analysis, there was
particular attention paid to the role of hormones and their epigenetic consequences,
studies sacrificing embryos and mice younger than 4 days old were not included in the
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analysis due to minimal sex characteristics present (Schlomer, 2013). Mice are altricial
which means that they do not start secreting hormones until after birth, unlike humans
which sexually differentiate in-utero. Therefore, it can be assumed that most sex
differences other than on the cellular level will not be apparent. It can also be inferred
that embryonic research uses both sexes due to the lack of most defining sexual
characteristics until postnatal day 4-5 (Schlomer, 2013).
The following inclusionary and exclusionary criteria was then applied to the
search (see Table 2). Data for the nine journals were mined from PubMed. A targeted
search was performed to find articles that met the inclusionary and exclusionary criteria
listed in Table 2. The search can be found in Appendix C. A program was written to
extract the title, data, authors, and affiliation of the first author. Another program was
written to separate American articles from international articles, in order to control for
other policies that would affect the proportion of sexes used. After the valid articles’
information was imported into an excel sheet, each was analyzed by hand for possible
excluding characteristics and for the three variables gathered.
Table 2: Inclusionary and Exclusionary Criteria.
Inclusionary
•
•
•
•

Exclusionary
•
•

USA affiliated first author
Uses mice
Relevant to human health
In-vivo and ex-vivo experiments

•
•
•
•
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Used animals other than mice
>90% one gender affected (i.e.
breast cancer)
Conditions involving the gonads
or genitals
X-linked conditions
BALB/c and Nu/Nu mice
Mice under 5 days old

The search was limited to the United States due to the NIH only funding US
researchers. In-vivo and ex-vivo experiments were particularly of interest due to
hormonal factors affecting cells being the primary reasoning of researchers to not use
females. BALB/c mice were excluded due to unusual male aggression seen in that strain
of mice leading to more females used. Nude mice were also excluded due to diminished
reproductive capability of homozygous females, leading to more readily available female
animals. Embryonic and neonatal mice under the age of P5 were excluded due to most
sexual differentiation not starting until postnatal day 5 due to their lack of precocial
hormone secretions.
Papers that did not include any in-vivo experiments, studied diseases that affected
primarily one gender, involved reproduction, involved X-linked diseases or mutations, or
researched urogenital diseases were all excluded from the PubMed search. The search
can be found in Appendix B along with the program used to extract data. The population
of papers using mice from the last ten years in the 9 journals totaled 14,819 articles
(Figure 1). The full population of biomedical research using mice between 2009 and 2018
was narrowed down to 2322 articles across nine journals and 3 fields known for their
disparate use of sexes (Figure 1).
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Figure 1: Applications of Search Criteria.

According to the NIH’s new policies: “Applicants must provide strong
justification for applications proposing to study only one sex. Such justification may
include the study of sex-specific conditions or phenomena (e.g., ovarian or prostate
cancer), acutely scarce resources (e.g., non-human primates), or investigations in which
the study of one sex is scientifically appropriate. The absence of evidence regarding sex
differences in an area of research does not constitute strong justification to study only one
sex.” These guidelines served as a basis for whether or not a study using only one sex
would be included. Statements such as, “prior research showed that female animals
consume more alcohol and therefore were excluded” were not considered to be valid
justification.
Due to availability of athymic mice and greater variation in group housed
BALB/c male mice, immunology is generally biased to use more females. BALB/c mice
are well known for their ability to produce plasmocytomas upon injection with mineral
oil. This is a reliable way to study monoclonal antibodies. Because of this unique
characteristic and the prevalence of abnormal male aggression skewing results, articles
using BALB/c strains were considered to have sound justification for using one sex and
therefore were excluded from analysis.
14

Furthermore athymic (nu/nu) mice were excluded from this study. This was due
to the fact that all athymic nude females have extremely reduced reproductive capability.
Moreover, the most humane way to study T cells requires the use of this particular breed
of mice. In turn, this leads to a surplus of homozygous females to use because the most
effective way to breed would require a homozygous male and a heterozygous female.
This unfortunately limits the usefulness of data obtained in immunology due to two of the
most commonly used strains being excluded. The results likely are skewed to favor more
sex differences analyses and more inclusion of male mice in studies. The categorization
of variables veered from Beery’s paper in that a definite cutoff was proposed for the use
of sexes to be roughly equal rather than assuming equal representation if they used both
sexes at all. A cutoff was also set for specification but this rarely mattered as most studies
either specified sex for all of their experiments or for none at all (Table 3). Furthermore,
the exact percentage of studies that did not uniformly use the same sexes throughout
experiments is not available, but can be assumed to be roughly 8 percent of articles based
on data from the journal Nature Neuroscience.
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Table 3: Description of Variables Analyzed and Classification.
Definition of Variables
Variable Categorization Definition
NIH Yes/No
Determined by the acknowledgement of such in the article.
Funding
Analysis Yes/No

Sex Male

Female

Both

Unspecified

Other

Indicated that there were no observed sex differences or
described statistical tests performed on sex
Used only males in 25% or more of the experiments and
both sexes or unspecified in the other 75%
Used males as controls and both as experimental animals
or the opposite
Used only females in 25% or more of the experiments and
both sexes or unspecified in the other 75%
Used females as controls and both as experimental animals
or the opposite
Used roughly equal parts males and females in more than
75% of experiments
Used mostly one sex but repeated the same exact study
with a smaller N of the other sex
Did not specify sex in more than 25% of experiment types
and used both in the other experiments
Unspecified in more than 75% of experiments and used
only males or only females in in less than 25%
Any instances that did not fit the above categories. Such
as, a study used males as controls and females as
experimental animals

For the large majority of articles (91.8 percent of Nature Neuroscience articles),
the sexes used would be specified in the methods section and would be uniform
throughout the study. A typical phrase found in the methods section would be: “Males
and females were used throughout this study.” However, females sometimes were
excluded for particular types of experiments such as behavioral measures. This is why
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there was a need for a specific cutoff rather than marking a study as ‘both’ if it included
both males and females at some point in the study.
Table 3 describes the cutoff percentage of experiments that used both sexes for it
to be considered approximately equal representation. The percentage of experiments as
stated above was only based on experimental types, not the individual N of males and
females. Only in-vivo experiments were included, if the study also performed in-vitro
experiments. Note that the ‘other’ category only contained 10 out of 2322 articles, mostly
within the pharmacology category.
Articles that met the inclusionary and exclusionary criteria analyzed for the
following variables: NIH funding, what sexes were used, whether or not they analyzed
for possible sex differences, and if they were published before or after the mandate. Chisquare tests were performed in SPSS (Statistical Package for the Social Sciences by IBM)
along with Pearson correlations in Excel.
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RESULTS

There have been significant improvements across fields in respect to reporting sex
differences analyses and to including both males and females. Figure 2 illustrates the
proportional differences in what sexes were used prior to the mandate versus how the
proportions changed after it was issued. Neuroscience, immunology, and pharmacology
all had significant increases in the amount of articles that used both males and females
after the mandate was issued (p<0.001). Note that chi square statistical analyses were
used. A limitation of this type of statistical test is that with a very large N, results may be
reported as very significant with a relatively small change.

Figure 2: Proportion of Each Sex Used by Field Pre- versus Post-Mandate
A. The figure indicates a significant increase in the use of both sexes in a given article (p<0.001) and a
significant decrease in the amount of articles that do not specify sex (p<0.001). This data combines all three
fields. B. In neuroscience there was a significant increase in the use of both sexes and a significant decrease
in the amount of unspecified carticles (p<0.001). C. In pharmacology there was a significant increase in the
amount of articles that used both males and females (p<0.001) D. There was also a significant increase in
the use of both sexes in immunology (p<0.001).
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A

Percentage of Articles Across Categories Analyzing Sex
Differences

18%
16%
14%
12%
10%
8%
6%
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Immunology

Neuroscience
2009-2015

B

Pharmacology
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Percentage of Articles within the Category 'Both' that
Analyzed Sex Differences

80%
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Pharmacology

Total

2016-2018

Figure 3: Percentage of Articles Analyzing Sex Differences
A. This figure indicates the percentage of articles per field that analyzed sex differences. This is subdivided
into prior to 2016, when the regulations enacted, and 2016-2018. Immunology articles analyze sex
differences at a significantly lower rate than neuroscience and pharmacology (p<0.001). Neuroscience and
pharmacology both saw significant increases in the percentage of articles that analyzed sex differences
while Immunology only increased by 1 percent.
B. This graph only takes into account articles that specified that they used both sexes in roughly equal
proportions. There isn’t a significant change overall or within neuroscience and immunology. However,
pharmacology showed a remarkable increase in sex differences analyses after 2015 (p<0.001). Note that the
percentages in B are proportional to the percentages in A. However the number of articles that used both
males and females is smaller than the total within each field, thus increasing the percentages found in B.
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Figure 3 compares the proportion of articles that analyze sex differences prior to
the mandate versus after its enactment. There was a significant increase in the overall
number of articles that analyzed sex differences after the mandate (p<0.001) (Figure 3A).
However, when looking only at articles that used both males and females, the percentage
of articles that analyzed sex differences did not change in any field but pharmacology
(p<0.001) (Figure 3B).
The difference between 3A and 3B is that 3A analyzed all articles within a given
field while 3B analyzes the subset of articles that are labeled as ‘both’. For example in
neuroscience for 3A, 47/653 neuroscience articles published before 2016 analyzed sex
differences and 57/ 429 articles published between 2016 and 2018 analyzed sex
differences. Meanwhile in 3B, 44/122 articles that used both males and females analyzed
sex differences articles prior to 2016. 54/186 articles that used both males and females
analyzed sex differences in 2016 onward. It is speculated that the difference between 3A
and 3B is due to the increase in proportion of articles that use both males and females in
neuroscience (seen in figure 2B). The proportion of neuroscience articles labeled as
‘both’ increased from 18.6% to 43.4% (Figure 2B). The overall increase in the percentage
of articles that used both sexes is strongly correlated with the increase in the overall
percentage of articles that analyzed sex differences (r= 0.822).
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Percentage of articles including both
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Figure 4: NIH funding Increased the Likelihood of Sex Differences Analysis and Sex Inclusion in
Pharmacology
A. A slightly larger percentage of NIH funded neuroscience articles included both males and females. A
significantly larger proportion of NIH funded pharmacology articles included both males and females
(p=0.001)
B. NIH funded studies had a larger amount of studies that analyzed sex differences in immunology
(p>0.05) and pharmacology (p=0.005). However in neuroscience, the inverse was seen (p=0.014).
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It was hypothesized that NIH funding would affect the inclusion of sexes and
analysis of sex differences. These relationships are indicated in Figure 4A and 4B.
Pharmacology seems to be the field that was the most positively affected by the NIH
mandate. In Figure 4B, significantly more NIH funded articles analyzed sex differences
in pharmacology after the 2016 mandate (p= 0.001). This relationship was not seen for
any field in articles published in 2009-2015 (not shown in a figure). However, for
neuroscience a negative relationship was seen between NIH funding and sex differences
analysis. This might be due to a much smaller number of articles lacking NIH funding in
Neuroscience compared to the other two fields, especially post 2016. For Figure 4A, a
slightly larger percentage of NIH funded neuroscience articles included both males and
females. A significantly larger proportion of NIH funded pharmacology articles included
both males and females (p=0.001).
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Figure 5: Percentage of Articles that Analyzed Sex Differences per Year per Field
The percentage of papers that analyzed for sex increased by 3.56 fold between 2015 and 2018 and overall
by 3.78 fold. There is a visible peak in sex differences analysis in 2012, the year after Beery’s publication,
and there is also an increase in analysis in 2016, the year that the plan was announced. Sex analysis doubled
in 2018 compared to 2017. However there was no overall change in the proportion of articles that used both
sexes to analyze sex differences. The large increase in Figure 2A is likely due to a generalized increase in
the use of both sexes.

The percentage of papers that analyzed for sex increased by 3.56 fold between
2015 and 2018 and overall by 3.78 fold, which can be seen in Figure 5. There is a visible
peak in sex differences analysis in 2012, the year after Beery’s publication, and there is
also an increase in analysis in 2016, the year that the mandate was enacted. Furthermore,
sex analysis doubled in 2018 compared to 2017. The upward trend seen in Figure 5
provides promise that there will be even more progress in the coming years as more
articles affected by the mandate are published. It can be speculated that much of the
change seen after 2016 was done under researchers’ own volition rather than in
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accordance to the mandate. The large majority of research directly affected by the FY
2017 regulations had not yet been published which indicates that researchers heard about
the new mandate and followed it even if it was not directly applicable to their research.
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DISCUSSION

In 1977, the FDA advised to exclude women of child bearing age from
drug trials due to possible effects of experimental medications on fertility and pregnancy.
These recommendations led to underrepresentation of women in clinical research into the
1990’s. Prior to the NIH Revitalization Act in 1993, clinical trials were not required to
study the effects of a medication on both men and women. After this Act was passed,
inclusion of women has increased to fifty percent (Department of Health and Human
Services, 2012). Of drugs withdrawn from the US market from 1997–2000, the US
Government Accountability Office (GAO) reported that 8 out of 10 drugs taken off the
market had greater adverse effects in women. The Food and Drug Administration does
not require researchers to perform preclinical research on both sexes of animals to bring a
drug to trial. This is an important topic to monitor as industries try to get the most
significant results in the most cost effective manner.
The NIH first announced plans to require researchers to analyze sex differences
and include both sexes in 2014. The official requirements were rolled out June 5, 2016.
Before this meta-analysis, there had not been a study that analyzed the relationship
between National Institutes of Health funding and the inclusion of both sexes in
preclinical research. Furthermore, a follow up to Beery’s 2011 paper analyzing sex
inclusion across fields has not been published. This meta-analysis aimed to quantify the
progress that has been made since Beery’s publication of 2009 data and define a
relationship between government funding and sex difference analysis. It was
hypothesized that there would be an increase in the inclusion of both sexes and increased
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analyses of sex differences over time. Furthermore, it was predicted that NIH funded
articles would be more likely to be inclusive of both sexes and analyze for sex
differences.
There are widespread sex differences in humans, many of which are conserved
across species. It is important for scientists conducting preclinical research to take into
account these differences when applying their research to humans. To understand the
biology of women or develop safe treatments for diseases of women one must do more
than study men and male animals. Pharmacology, immunology, and neuroscience in
particular are fields with important sex differences that need to be studied.
Studying sex differences is important for neuroscience due to their presence
across cellular, anatomical, and behavioral levels. These differences include increased
lateralization in males, differential gene expression independent of hormones in the brain,
and neuroprotective effects of the gonadal steroid estrogen (Killgore, 2001; Cahill, 2006;
Koren, 2014). Furthermore, women are predisposed to the neurodegenerative disease
multiple sclerosis (MS) which falls under immunology and neuroscience (Klein, 2016).
Estrogen has been hypothesized to play an important role in autoimmune diseases such as
MS and Grave’s disease (Klein, 2016). Furthermore, women have more active immune
systems which can lead to adverse effects of vaccines and other immunological drugs. In
Pharmacology, many metabolism genes are differentially expressed based on cellular sex
(Soldin, 2011). Lower gastric pH is also common in men which can contribute to
enhanced or reduced drug absorption (Soldin, 2009). In summary, sex differences are due
to X chromosome inactivation, anatomical differences, and exposure to different levels of
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sex hormones. The differences previously mentioned have the capacity to affect the
health of women and men if they are not properly analyzed in preclinical research.
According to the performed analyses, there was a significant overall increase in
the number of articles that analyzed sex differences after 2015 (p<0.001, Figure 3A).
However, when only including articles that included both sexes, there was only an
increase in sex differences analyses for pharmacology (Figure 3B). Furthermore, there
was an overall increase in the inclusion and specification of sexes (p<0.001). The
inclusion of sexes and analysis of sex differences varied across the three examined fields.
All fields showed significant improvements in the inclusion of both sexes after the
mandate was enacted (Figure 2 A-D). Neuroscience also showed a significant increase in
the number of articles that specified sex (Figure 2B). While it is promising that these
fields have moved in the right direction in terms of sex inclusion, immunology still only
included both sexes in 14.5 percent of research between 2016 and 2018 (Figure 2D).
Neuroscience showed the largest improvement in inclusiveness, and used both sexes in
42 percent of research between 2016 and 2018.
Neuroscience and pharmacology improved in regard to sex differences analyses
over time (Figure 5). The amount of articles that analyzed sex differences in these two
fields doubled between 2017 and 2018. In respect to the proportion of articles that
analyzed sex differences within the ‘both’ category, only pharmacology articles showed
an improvement (p<0.001; Figure 3A-B).
Immunology did not improve in respect to specification of sex or in analysis of
sex differences even though the field has started to include more males. It is possible that
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because the field primarily uses females, researchers do not believe that the mandate
applies to them. Furthermore, pharmacology was the only field that had an interaction
between NIH funding and the likelihood of analyzing sex differences and including both
sexes post 2015 (Figure 4A and B; p<0.001). This could mean that pharmacology, in
respect to sex analysis, was most affected by the mandate.
While both pharmacology and neuroscience have improved dramatically in
comparison to 2009, there is still a long way to go. For 2018, the overall rate of articles
that analyzed for sex differences was only 16.4 percent. Increasing that statistic to near
one hundred percent in relevant articles would be ideal. Furthermore, almost seventy
percent of articles are still using either one sex or not specifying what sexes were used.
This is unacceptable unless this statistic continues in the positive direction. The only
current repercussion issued by the NIH is that grant applications will be rejected if they
do not address sex differences in their proposed experimental design. I propose that
further repercussions such as grant repayment, and future disqualification from funding
should be taken if it is found that a researcher failed to address sex differences in their
publication as it was stated in their grant application.
Several limitations are present in this data. This meta- analysis only focused on
papers that included in-vivo experiments. However, it is important to acknowledge
cellular and genetic sex differences found in animals that are independent of hormones.
Furthermore, while mice are the most commonly used model organism, many
pharmaceutical companies use multiple species, leading to a possibly less representative
population of articles. Mice also comprise fifty percent of the model organisms used, so
this research may not be representative of the other half of preclinical research. Lastly,
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this analysis only accounts for two years after the implementation of the new NIH policy,
so it is possible that research conducted prior to fiscal year 2017 is being published with
no requirements to include both sexes. Furthermore, several discrepancies in 2009 data
were found between this meta-analyisis and Beery’s paper. According to her paper, the
rate of specification of sex in 2009 was 75, 80, and 35 percent for neuroscience,
pharmacology, and immunology respectively (Figure 8; Beery, 2011). My analysis
resulted in a specification rate of 50, 75, and 40 for these fields in 2009. This is justifiable
since hers study used more types of animals than just mice and a less strict classification
system than the one used in this study (Beery, 2011).
It was hypothesized that an increase in the inclusion of both sexes and sex
differences analysis would increase after the enactment of the mandate in 2016.
Furthermore, it was expected that NIH funded research would include both sexes and
analyze sex differences more often than research with other sources of funding. All fields
did significantly increase in the proportion of articles that used both sexes post-mandate
(Figure 2; p<0.001). No relationship was found between NIH funding and sex differences
analysis or sex inclusion in immunology. For pharmacology, the presence of NIH funding
post 2015, increased the likelihood that a given article would analyze sex differences and
include both sexes (Figure 4A-B). This relationship was not seen in pharmacology for
articles published between 2009 and 2015. This finding supports the hypothesis that an
increase in sex differences analysis and sex inclusion would be seen after the mandate’s
enactment.
While there were significant improvements seen in the three fields studied, it
should be noted that the mandate itself reflects requirements for grants rather than papers
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published. Furthermore, most research funded by grants accepted during the fiscal year of
2017 has not been published yet. It could be that the improvements seen throughout the
years are due to a changing opinion within the scientific community of studying sex
differences. This is supported by the finding that more research funded by other sources
than the NIH in the field of neuroscience analyzed sex differences post 2015 (Figure 4B).
If the new results are due to a changing environment, hopefully in the coming years, as
more research directly affected by the mandate is published, there will be even larger
increases in sex differences analyses and sex inclusion.
In conclusion, there are many widespread sex differences present in the fields of
pharmacology, immunology, and neuroscience. In order to ensure proper medical
treatment of women, these differences should be addressed in preclinical research. This
analysis indicates that the number of articles that use both sexes in their research has
increased since the implementation of the new policies. There have also been increases in
the specification of sex and the analysis of sex differences. The current statistics of
articles analyzing sex differences (16.4 percent), and articles including both sexes (36.4
percent) are unacceptable and need to increase in the coming years. A positive trend
could continue into 2019 and beyond, due to the fact that researchers funded in 2016 and
after likely have not yet published their research. It is possible that there could be a
significant uptick in articles using both sexes in the coming years. This should be
monitored and it is recommended that a similar study be conducted by 2022.
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APPENDIX A: SUPPLEMENTAL FIGURES
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Figure 6: Proportion of Sexes used per Year across all Fields
Indicates the proportion of sexes used each year across fields.
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Percentage of Sexes used in Research over Time
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Figure 7: Percentage of Sexes used per Field 2009-2018.
A. Neuroscience has increased in specification by 40 percent while increasing the inclusion of both sexes
by the same amount. B. There has been a slight increase in the amount of articles that used both sexes in
Immunology. C. The inclusion of both sexes increased by 25 percent between 2015 and 2018.
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(Taken from Annaliese Beery: Sex bias in neuroscience and biomedical research.)
Figure 8: Beery 2009 Data by Field
Data from 2009 indicated that immunology analyzed sex differences less than 5 percent of the time while
neuroscience and pharmacology analyzed them at rates of 20 and 30 percent.
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APPENDIX B: SUPPLEMENTAL METHODS

Search conducted on PubMed:
("mice"[Mesh terms] OR "mouse"[All Fields] OR "mice"[All fields] NOT "Genetic
Diseases, X-Linked"[MeSH Terms] AND ("2009/01/01"[PDAT] : "2018/12/31"[PDAT])
NOT "In-vitro Techniques"[mesh terms] NOT "Genitalia"[mesh terms] NOT
"breast"[mesh terms] NOT Review[ptyp] NOT "Reproduction"[mesh terms] NOT
"veterinary"[all fields] NOT "Genetic Diseases, Y-Linked"[Mesh terms] NOT
"Embryo"[all fields] NOT "Female Urogenital Diseases"[mesh terms] NOT "Mental
Retardation, X-Linked"[mesh terms] NOT "Male Urogenital Diseases" NOT "Herpes
Genitalis"[mesh terms] NOT "Alphapapillomavirus"[mesh terms] AND
("USA"[affiliation] OR "United States"[Affiliation] OR United States of
America[Affiliation]) NOT "Animal Diseases"[mesh terms] AND "loattrfull text"[sb]
NOT Cercopithecidae NOT Artiodactyla NOT Carnivora NOT Cetacea NOT
Lagomorpha NOT Perissodactyla NOT Guinea Pigs NOT Chinchilla NOT Cuniculidae
NOT Rats NOT Gerbillinae NOT Mole Rats NOT Myoxidae NOT Octodon NOT
Porcupines NOT Sciuridae NOT Chiroptera NOT scandentia NOT Sirenia NOT Hyraxes
NOT Insectivora NOT Marsupialia NOT Monotremata NOT Proboscidea Mammal NOT
Xenarthra NOT Birds NOT Amphibians NOT Fishes NOT Reptiles NOT Invertebrates
NOT Chlamydia NOT hamsters NOT rabbit NOT dog NOT cat NOT maternal NOT
HPV NOT "Mice, Inbred BALB C"[Mesh terms] NOT Mice, Nude) AND "Plos
pathogens"[Journal]

Program
The following is the program that was written to extract the following from the results of
the above PubMed search: title, first author, first author affiliation, year of publication of
each article. The articles were then grouped into USA affiliated and non-USA affiliated
first authors, only the former was used in analysis.
%% Written by:
Phoenix Throckmorton
%%Purpose: This script will load string data from a .txt file and
extract
%%important information. This information will be filtered and
organized
%%into an excel spread sheet for presentation.
tic
%The script is organized as follows:
%
1. INPUT VARIABLES
%
2. Variable Allocation
%
3. Extracting Data
%
4. Post Processing
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%
5. Outputting Data
clear all;
close all;

%% 1.INPUT VARIABLES (Edit this)
%%Change these as needed. Do not edit any other part of the script
%enter directory where ALL files are located:
file_directory = 'C:\Users\pthro\Desktop\NicolesProgram';
%enter name of .txt file, including .txt extension
txt = 'Neuron.txt';
%enter the name of the exporting excel spreadsheet, including .xlsx
%extension
excel = 'USA_Neuron.xlsx';
%enter the name of the NON USA exporting spreadsheet, including .xlsx
NONUSA_excel = 'NONUSA_Neuron.xlsx';
%% 2.Variable Allocation
%This section opens files and prepares/converts variables for data
transfer
%set appropriate file directories and names
cd(file_directory);
txt_full = strcat(file_directory, '\', txt);
excel_full = strcat(file_directory, '\', excel);
%Prepares the .txt for file extraction, string by string
ID = fopen(txt_full);
data = textscan(ID, '%s');
size = length(data{1});
%%Preallocate other variables for data extraction
%%title
%counts how many times the initialization and termination terms occur
initial_title_count = 0;
final_title_count = 0;
%keeps track of the indices for each occurence
title_index = 0;
%%year
%counts how many times the initialization and termination terms occur
initial_year_count = 0;
final_year_count = 0;
%keeps track of the indices for each occurence
year_index = 0;
%%firstname
%counts how many times the initialization and termination terms occur
initial_firstname_count = 0;
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final_firstname_count = 0;
%keeps track of the indices for each occurence
firstname_index = 0;
%%lastname
%counts how many times the initialization and termination terms occur
initial_lastname_count = 0;
final_lastname_count = 0;
%keeps track of the indices for each occurence
lastname_index = 0;
%%affiliation
%counts how many times the initialization and termination terms occur
initial_affiliation_count = 0;
final_affiliation_count = 0;
%keeps track of the indices for each occurence
affiliation_index = 0;
%% 3.Extracting data Index
%get the locations of all of the article titles, year, first name, last
%name, and affiliation
%This loop is performed first since only one instance of each term
appears
%for each article
for i = 1:size
%check if an article title is to be shown, and save bounds
if contains(data{1}{i},'<ArticleTitle>') == 1
initial_title_count = initial_title_count + 1;
title_index(initial_title_count,1) = i;
end
if contains(data{1}{i},'</ArticleTitle>') == 1
final_title_count = final_title_count + 1;
title_index(final_title_count,2) = i;
end
%check if year is to be shown, and save bounds
if contains(data{1}{i},'<PubDate>') == 1
initial_year_count = initial_year_count + 1;
year_index(initial_year_count,1) = i;
end

end

if contains(data{1}{i},'</PubDate>') == 1
final_year_count = final_year_count + 1;
year_index(final_year_count,2) = i;
end

%initialize synchronization counters for initial and final bounds
size_sync = length(year_index(:,1));
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%now that the total number of articles is known, run through again
between
%each bound and grab the first author and affiliation and pair them
for j = 1:size_sync
if j == size_sync
loop_condition = size;
%prevents strange behavior at end of
loop
else
loop_condition = title_index(j+1,1);
end
%check if author lastname is to be shown, and save bounds
for k = title_index(j,1): loop_condition
if contains(data{1}{k},'<LastName>') == 1
initial_lastname_count = initial_lastname_count + 1;
lastname_index(initial_lastname_count,1) = k;
end
if contains(data{1}{k},'</LastName>') == 1
final_lastname_count = final_lastname_count + 1;
lastname_index(final_lastname_count,2) = k;
break; %TERMINATES AFTER FIRST OCCURENCE
end
end
%check if author firstname is to be shown, and save bounds
for k = title_index(j,1): loop_condition
if contains(data{1}{k},'<ForeName>') == 1
initial_firstname_count = initial_firstname_count + 1;
firstname_index(initial_firstname_count,1) = k;
end
if contains(data{1}{k},'</ForeName>') == 1
final_firstname_count = final_firstname_count + 1;
firstname_index(final_firstname_count,2) = k;
break %TERMINATES AFTER FIRST OCCURENCE
end
end
%check if affiliation is to be shown, and save bounds
for k = title_index(j,1): loop_condition
if contains(data{1}{k},'<AffiliationInfo>') == 1
initial_affiliation_count = initial_affiliation_count + 1;
affiliation_index(initial_affiliation_count,1) = k;
end

end

if contains(data{1}{k},'</AffiliationInfo>') == 1
final_affiliation_count = final_affiliation_count + 1;
affiliation_index(final_affiliation_count,2) = k;
break %TERMINATES AFTER FIRST OCCURENCE
end

end
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%do a second pass to truly filter out the year locations
for j = 1:size_sync
for k = year_index(j,1): year_index(j,2)
if contains(data{1}{k},'<Year>') == 1
year_index(j,1) = k;
end
if contains(data{1}{k},'</Year>') == 1
year_index(j,2) = k;
end
end

end

%%3.B Raw Data Extraction
%Grab the data using the determined indeces
%preallocate data storing variables based on now known number of
articles
title = strings(size_sync,1);
year = strings(size_sync,1);
first = strings(size_sync,1);
last = strings(size_sync,1);
affiliation = strings(size_sync,1);
institution = strings(size_sync,1);
for j = 1:size_sync
%For article titles
for k = title_index(j,1): title_index(j,2)
title(j) = strcat(title(j),{' '},data{1}{k}); %adds the entire
title line
end
%For years
for k = year_index(j,1): year_index(j,2)
year(j) = strcat(year(j),{' '},data{1}{k}); %adds the entire
year line
end
%For lastnames
for k = lastname_index(j,1): lastname_index(j,2)
last(j) = strcat(last(j),{' '},data{1}{k}); %adds the entire
lastname line
end
%For firstnames
for k = firstname_index(j,1): firstname_index(j,2)
first(j) = strcat(first(j),{' '},data{1}{k}); %adds the entire
firstname line
end
%For affiliations
for k = affiliation_index(j,1): affiliation_index(j,2)
affiliation(j) = strcat(affiliation(j),{' '},data{1}{k}); %adds
the entire affiliation line
end
%Determination of university
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if contains(affiliation(j), 'inc.')
contains(affiliation(j),'incorporated')
|| contains(affiliation(j),
contains(affiliation(j), 'corporation')
|| contains(affiliation(j),

end

||
...
'Inc.') ||
...
'Corporation')

institution(j) = 'Biotech';
elseif contains(affiliation(j), 'Hospital')
institution(j) = 'Hospital';
elseif contains(affiliation(j), 'University')
institution(j) = 'University';
else
institution(j) = ' ';
end

%% 4.Post Processing
%%Remove any articles that were published outside of the US
%preallocate based on total files
junk_title = strings(size_sync,1);
junk_year = strings(size_sync,1);
junk_first = strings(size_sync,1);
junk_last = strings(size_sync,1);
junk_affiliation = strings(size_sync,1);
junk_institution = strings(size_sync,1);
NONUSA_counter = zeros(size_sync,1);
%Remove any information that is not desired for the final output
%for title
title(1:size_sync)
title(1:size_sync)
title(1:size_sync)
title(1:size_sync)
title(1:size_sync)
title(1:size_sync)

=
=
=
=
=
=

erase(title(1:size_sync),
erase(title(1:size_sync),
erase(title(1:size_sync),
erase(title(1:size_sync),
erase(title(1:size_sync),
erase(title(1:size_sync),

' <ArticleTitle>');
'<ArticleTitle> ');
'<ArticleTitle>');
' </ArticleTitle>');
'</ArticleTitle> ');
'</ArticleTitle>');

%for first name
first(1:size_sync)
first(1:size_sync)
first(1:size_sync)
first(1:size_sync)
first(1:size_sync)
first(1:size_sync)

=
=
=
=
=
=

erase(first(1:size_sync),
erase(first(1:size_sync),
erase(first(1:size_sync),
erase(first(1:size_sync),
erase(first(1:size_sync),
erase(first(1:size_sync),

' <ForeName>');
'<ForeName> ');
'<ForeName>');
' </ForeName>');
'</ForeName> ');
'</ForeName>');

%for lastname
last(1:size_sync)
last(1:size_sync)
last(1:size_sync)
last(1:size_sync)
last(1:size_sync)

=
=
=
=
=

erase(last(1:size_sync),
erase(last(1:size_sync),
erase(last(1:size_sync),
erase(last(1:size_sync),
erase(last(1:size_sync),
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' <LastName>');
'<LastName> ');
'<LastName>');
' </LastName>');
'</LastName> ');

last(1:size_sync) = erase(last(1:size_sync), '</LastName>');
%for year
year(1:size_sync)
year(1:size_sync)
year(1:size_sync)
year(1:size_sync)
year(1:size_sync)
year(1:size_sync)

=
=
=
=
=
=

erase(year(1:size_sync),
erase(year(1:size_sync),
erase(year(1:size_sync),
erase(year(1:size_sync),
erase(year(1:size_sync),
erase(year(1:size_sync),

%for affiliation
affiliation(1:size_sync)
<AffiliationInfo>');
affiliation(1:size_sync)
'<AffiliationInfo> ');
affiliation(1:size_sync)
'<AffiliationInfo>');
affiliation(1:size_sync)
</AffiliationInfo>');
affiliation(1:size_sync)
'</AffiliationInfo> ');
affiliation(1:size_sync)
'</AffiliationInfo>');
affiliation(1:size_sync)
<Affiliation>');
affiliation(1:size_sync)
'<Affiliation> ');
affiliation(1:size_sync)
'<Affiliation>');
affiliation(1:size_sync)
</Affiliation>');
affiliation(1:size_sync)
'</Affiliation> ');
affiliation(1:size_sync)
'</Affiliation>');

' <Year>');
'<Year> ');
'<Year>');
' </Year>');
'</Year> ');
'</Year>');

= erase(affiliation(1:size_sync), '
= erase(affiliation(1:size_sync),
= erase(affiliation(1:size_sync),
= erase(affiliation(1:size_sync), '
= erase(affiliation(1:size_sync),
= erase(affiliation(1:size_sync),
= erase(affiliation(1:size_sync), '
= erase(affiliation(1:size_sync),
= erase(affiliation(1:size_sync),
= erase(affiliation(1:size_sync), '
= erase(affiliation(1:size_sync),
= erase(affiliation(1:size_sync),

for j = 1:size_sync
%check to see if the article is US affiliated
if contains(affiliation(j), 'USA') || contains(affiliation(j),
'United States')

end

else %keeps track of where non US files are
NONUSA_counter(j) = 1;
end

%determines where NONUSA Data occurs
c = 0;
for j = 1:size_sync
if NONUSA_counter(j) == 1
c = c + 1;
NONUSA_counter(j) = 1;
junk_title(c) = title(j);
junk_first(c) = first(j);
junk_last(c) = last(j);
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end

end

junk_affiliation(c) = affiliation(j);
junk_institution(c) = institution(j);
junk_year(c) = year(j);

%deletes data where appropriate
%convert to logical indexing format
NONUSA_counter = NONUSA_counter == 1;
%apply conditions
title(NONUSA_counter,:) = [];
year(NONUSA_counter,:) = [];
first(NONUSA_counter,:) = [];
last(NONUSA_counter,:) = [];
affiliation(NONUSA_counter,:) = [];
institution(NONUSA_counter,:) = [];
%% 5. Data Output
%create the headings for excel data:
heading = strings(1,6);
heading(1) = 'Article Title';
heading(2) = 'Year';
heading(3) = 'Last Name';
heading(4) = 'First Name';
heading(5) = 'Affiliation';
heading(6) = 'Institution';
final_data = horzcat(title, year, last, first, affiliation,
institution);
final_data = vertcat(heading,final_data);
xlswrite(excel, final_data);
NON_USA_data = horzcat(junk_title, junk_year, junk_last, junk_first,
...
junk_affiliation, junk_institution);
NON_USA_data = vertcat(heading,NON_USA_data);
xlswrite(NONUSA_excel, NON_USA_data);
toc
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